Clinical efficacy of Ranibizumab combined with 577nm multi-point scanning matrix laser photocoagulation in the treatment of DME patients / 国际眼科杂志(Guoji Yanke Zazhi)

ABSTRACT

@#AIM: To explore the clinical effect of leizhumab combined with 577nm multi-point scanning matrix laser photocoagulation in the treatment of diabetic macular edema(DME).<p>METHODS:Totally 127 eyes of 94 patients(January 2017-June 2018)with DME were selected. According to the different treatment methods, RA group was divided into two groups. RA group was only treated with razumab group the patients in this group were treated with razumab injection; RL group razumab combined with 577nm multi-point scanning matrix laser group the patients in this group were treated with razumab combined with 577nm multi-point scanning matrix laser photocoagulation. To observe the treatment effect of RA group and RL group 1mo after three times of leizhumab injection; to check the visual improvement of RA group and RL group before treatment and 1mo, 3mo and 6mo after three times of leizhumab injection; to detect the macular fovea thickness(CMT)of RA group and RL group by optical coherence tomography(OCT); to detect the retinal neogenesis by FFA Vascular leakage area and postoperative complications.<p>RESULTS: The effective rate(100%)of the patients in the combined group was higher than that in the single group(97%), but the difference was not statistically significant(<i>P</i>>0.05). Before treatment, the BCVA of the two groups of patients were 0.57±0.20 and 0.56±0.18(<i>P</i>>0.05). After completing three injections of ranibizumab, the BCVA of the single group of patients at 1, 3, and 6mo were 0.39±0.05, 0.23±0.06,0.18±0.05, the BCVA of the combined group were 0.28±0.08,0.18±0.07, 0.12±0.06, the BCVA of the combined group was better than the control group(<i>P</i><0.001). Before treatment, the CMT of the two groups of patients were 389±42.54 and 386±38.25, respectively(<i>P</i>>0.05).After completing three injections of ranibizumab, the CMT of the single group at 1, 3,and 6mo were 333.84±38.18, 297.12±27.10, 278.15±26.24μm, the CMT of the combined group were 315.04±39.07, 274.35±28.63, 253.65±25.91μm, the improvement of the CMT of the combined group was better than that of the single group(<i>P</i><0.001). Before treatment, the leakage area of retinal neovascularization in the two groups was 22.31±3.26 and 21.98±3.18mm2(<i>P</i>>0.05). After the injection of ranibizumab was completed 3 and 6mo, the single group leaked The areas were 18.34±2.19, 7.81±1.28mm2, and the leakage area of the combined group were 14.92±1.98, 5.39±1.42mm2, respectively(<i>P</i><0.001). Complications occurred in 3 eyes of a single group of patients and complications in 4 eyes of a combined group(<i>P</i>>0.05).<p>CONCLUSION: Leizhumab and 577nm multi-point scanning matrix laser photocoagulation are effective and safe in the treatment of DME patients, but the long-term effect of leizhumab combined with 577nm multi-point scanning matrix laser group is better than that of single line intravitreal injection of leizhumab.